1.42
price down icon2.07%   -0.03
after-market 시간 외 거래: 1.39 -0.03 -2.11%
loading
전일 마감가:
$1.45
열려 있는:
$1.41
하루 거래량:
2.18M
Relative Volume:
0.42
시가총액:
$310.69M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.6698
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
-0.70%
1개월 성능:
-12.35%
6개월 성능:
-49.29%
1년 성능:
-59.08%
1일 변동 폭
Value
$1.39
$1.49
1주일 범위
Value
$1.375
$1.53
52주 변동 폭
Value
$1.23
$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
명칭
Allogene Therapeutics Inc
Name
전화
(650) 457-2700
Name
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
직원
361
Name
트위터
@AllogeneTx
Name
다음 수익 날짜
2025-03-04
Name
최신 SEC 제출 서류
Name
ALLO's Discussions on Twitter

ALLO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.42 310.69M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-14 업그레이드 Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 재개 Oppenheimer Outperform
2024-05-31 개시 Piper Sandler Overweight
2024-01-05 다운그레이드 Guggenheim Buy → Neutral
2024-01-05 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 개시 Citigroup Buy
2023-06-26 재개 Oppenheimer Outperform
2023-03-21 개시 Bernstein Mkt Perform
2023-01-24 업그레이드 JP Morgan Neutral → Overweight
2023-01-06 업그레이드 Robert W. Baird Neutral → Outperform
2022-12-12 다운그레이드 BofA Securities Buy → Underperform
2022-08-10 다운그레이드 Raymond James Outperform → Mkt Perform
2022-07-15 업그레이드 Goldman Neutral → Buy
2022-06-03 개시 Robert W. Baird Neutral
2022-02-28 재확인 B. Riley Securities Buy
2021-10-20 개시 Cowen Outperform
2021-10-08 다운그레이드 Goldman Buy → Neutral
2021-10-08 다운그레이드 Stifel Buy → Hold
2021-09-23 업그레이드 Raymond James Mkt Perform → Outperform
2021-06-21 재개 Jefferies Buy
2021-05-20 업그레이드 Truist Hold → Buy
2021-05-14 개시 B. Riley Securities Buy
2021-01-26 업그레이드 Stifel Hold → Buy
2020-12-10 재개 H.C. Wainwright Buy
2020-11-24 개시 BofA Securities Buy
2020-10-23 개시 RBC Capital Mkts Outperform
2020-06-01 다운그레이드 Raymond James Outperform → Mkt Perform
2020-05-29 재확인 H.C. Wainwright Buy
2020-05-19 업그레이드 ROTH Capital Neutral → Buy
2020-05-15 업그레이드 Guggenheim Neutral → Buy
2020-05-14 재확인 H.C. Wainwright Buy
2020-05-14 다운그레이드 SunTrust Buy → Hold
2020-04-13 개시 SunTrust Buy
2020-03-13 개시 H.C. Wainwright Buy
2020-03-05 개시 Stifel Hold
2020-02-24 개시 Berenberg Hold
2019-12-18 개시 JMP Securities Mkt Outperform
2019-11-04 개시 Canaccord Genuity Buy
2019-08-09 개시 BTIG Research Buy
2019-06-05 개시 ROTH Capital Neutral
2019-05-31 개시 Guggenheim Neutral
2019-05-23 개시 Stifel Hold
2019-03-29 개시 Piper Jaffray Overweight
모두보기

Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스

pulisher
Apr 10, 2025

Allogene received FDA Fast-track statuses for its dual CAR-Therapy - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 08, 2025

FDA Grants Three Fast Track Tags To Allogene's Autoimmune Disease Drug - Barchart.com

Apr 08, 2025
pulisher
Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene's ALLO-329 Granted Three FDA Fast Track Designations - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases - marketscreener.com

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - The Manila Times

Apr 07, 2025
pulisher
Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Groundbreaking Triple FDA Fast Track: Allogene's New CAR T Targets Multiple Autoimmune Diseases - Stock Titan

Apr 07, 2025
pulisher
Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics CEO sells $91,469 in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com

Mar 18, 2025
pulisher
Mar 17, 2025

7th Annual Allogeneic Cell Therapies Summit - pharmaphorum

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025
pulisher
Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlight - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene stock upgraded at Citizens post Q4 (ALLO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics: Q4 Earnings Snapshot - The Wilton Bulletin

Mar 14, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations - Investing.com India

Mar 13, 2025

Allogene Therapeutics Inc (ALLO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
자본화:     |  볼륨(24시간):